ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesD61.1

D61.1

Billable

Drug-induced aplastic anemia

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/05/2025

Code Description

ICD-10 D61.1 is a billable code used to indicate a diagnosis of drug-induced aplastic anemia.

Key Diagnostic Point:

Drug-induced aplastic anemia is a serious hematological condition characterized by the failure of the bone marrow to produce adequate amounts of blood cells, leading to pancytopenia (a reduction in red blood cells, white blood cells, and platelets). This condition can be triggered by various medications, including certain antibiotics, anticonvulsants, and non-steroidal anti-inflammatory drugs (NSAIDs). The pathophysiology involves an immune-mediated destruction of hematopoietic stem cells or direct toxicity to the bone marrow. Patients may present with symptoms such as fatigue, weakness, increased susceptibility to infections, and bleeding tendencies due to low platelet counts. Diagnosis typically involves blood tests showing low blood cell counts and a bone marrow biopsy revealing hypocellularity. Management may include discontinuation of the offending drug, supportive care, and in severe cases, immunosuppressive therapy or bone marrow transplantation. Early recognition and intervention are crucial to improve outcomes.

Code Complexity Analysis

Complexity Rating: Medium

Medium Complexity

Complexity Factors

  • Identification of the specific drug causing the aplastic anemia.
  • Differentiation from other types of anemia and bone marrow failure syndromes.
  • Need for comprehensive patient history and medication review.
  • Potential for multiple underlying causes of bone marrow failure.

Audit Risk Factors

  • Inadequate documentation of drug history.
  • Failure to specify the type of aplastic anemia.
  • Lack of supporting lab results.
  • Misclassification of anemia type.

Specialty Focus

Medical Specialties

Hematology

Documentation Requirements

Detailed patient history, including medication use, lab results, and treatment plans.

Common Clinical Scenarios

Patients presenting with unexplained anemia, recurrent infections, or bleeding episodes.

Billing Considerations

Close monitoring of blood counts and potential need for transfusions or immunosuppressive therapy.

Primary Care

Documentation Requirements

Comprehensive medication review and assessment of symptoms related to anemia.

Common Clinical Scenarios

Initial evaluation of patients with fatigue and pallor, followed by referral to hematology.

Billing Considerations

Awareness of common medications that can induce aplastic anemia.

Coding Guidelines

Inclusion Criteria

Use D61.1 When
  • According to ICD
  • 10 coding guidelines, D61
  • 1 should be used when the aplastic anemia is specifically attributed to drug exposure
  • Coders must ensure that the documentation clearly indicates the causative agent and that other causes of aplastic anemia are ruled out

Exclusion Criteria

Do NOT use D61.1 When
No specific exclusions found.

Related ICD-10 Codes

Related CPT Codes

85025CPT Code

Complete blood count (CBC) with differential

Clinical Scenario

Used to evaluate the severity of anemia and monitor blood counts in patients with D61.1.

Documentation Requirements

Document the reason for the CBC and any relevant clinical findings.

Specialty Considerations

Hematologists may require more frequent monitoring of blood counts.

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The transition to ICD-10 has allowed for more specific coding of drug-induced aplastic anemia, improving the accuracy of data collection and reimbursement processes. It emphasizes the importance of detailed documentation regarding medication history and clinical findings.

ICD-9 vs ICD-10

The transition to ICD-10 has allowed for more specific coding of drug-induced aplastic anemia, improving the accuracy of data collection and reimbursement processes. It emphasizes the importance of detailed documentation regarding medication history and clinical findings.

Reimbursement & Billing Impact

reimbursement processes. It emphasizes the importance of detailed documentation regarding medication history and clinical findings.

Resources

Clinical References

  • •
    American Society of Hematology

Coding & Billing References

  • •
    American Society of Hematology

Frequently Asked Questions

What are the common drugs associated with drug-induced aplastic anemia?

Common drugs include chloramphenicol, sulfonamides, certain anticonvulsants, and NSAIDs. It is crucial to review the patient's medication history to identify potential culprits.